Equities

Intellipharmaceutics International Inc

Intellipharmaceutics International Inc

Actions
  • Price (CAD)0.08
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta0.4381
Data delayed at least 15 minutes, as of Mar 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. It also provides analytical services.

  • Revenue in CAD (TTM)1.25m
  • Net income in CAD-4.37m
  • Incorporated2009
  • Employees33.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vaxil Bio Ltd0.00-453.00k2.07m----2.39-----0.0033-0.00330.000.00630.00-------32.72-85.96-41.91-188.84------------0.00------40.77------
Vitality Products Inc775.08k-356.72k2.30m--------2.96-0.0086-0.00860.0187-0.03170.68121.015.32---31.35-31.33----72.6673.77-46.02-47.850.1874-315.87-----3.9214.6412.87------
Intellipharmaceutics International Inc1.25m-4.37m2.67m33.00------2.14-0.1321-0.13210.0377-0.5360.6027--3.37---211.39-132.15-----88.96---350.72-499.37---19.36-------58.7543.78------
Radient Technologies Inc3.15m-11.30m2.73m33.00------0.8664-0.0216-0.02160.006-0.02780.11081.566.00---39.76-67.36---118.27-3.911.66-359.00-534.110.0251-3.58----45.4965.3069.41--200.33--
Genix Pharmaceuticals Corp10.83k-4.23m2.96m--------273.43-0.0714-0.07140.0002-0.02020.00490.05021.89---191.99-54.69-476.20-68.5923.08---39,036.01-5,345.880.0541-10.33-------50.60-309.27------
Lifeist Wellness Inc21.66m-14.13m2.98m72.00--0.8063--0.1376-0.0287-0.02870.04510.00621.273.327.94---82.93-62.71-158.05-78.8130.6617.06-65.22-136.110.4707-257.620.268---1.85--24.45------
Therma Bright Inc25.80k-2.88m3.19m----1.72--123.51-0.0115-0.01150.00010.00580.00760.00230.115---84.40-220.66-165.23-444.5798.45---11,152.48-10,853.160.0447-184.520.0411---82.8611.1335.93--40.15--
Data as of Mar 22 2024. Currency figures normalised to Intellipharmaceutics International Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.